ClinicalTrials.gg
CompletedNCT02226991Updated Aug 27, 2014

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

A Phase 1 interventional study of Tipranavir and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Study to investigate the effects of steady-state Efavirenz (600 mg QD) on the steady-state pharmacokinetics of Tipranavir (500 mg BID) coadministered with Ritonavir (200 mg BID)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 60 years of age inclusive
  2. A (BMI) between 18 and 29.9 kg/m2
  3. Signed prior to trial participation
  4. Ability to swallow multiple large capsules without difficulty
  5. Acceptable laboratory values that indicate adequate baseline organ function at screening visit

    • Laboratory values are considered to be acceptable if the severity of any parameter is ≤Grade 1, based on the Division of AIDS (DAIDS)/AIDS Clinical Trials Group (ACTG) Grading Scale
    • All abnormal laboratory values >Grade 1 are subject to approval by the BI trial clinical monitor
  6. Acceptable medical history, physical examination, and 12-lead at screening
  7. Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study:

    • Grapefruit or grapefruit juice, red wine, Seville oranges, St. John's Wort, and Milk Thistle
  8. Willingness to abstain from alcohol starting 3 days prior to administration of any study medication up to the end of the study
  9. Willingness to abstain from the following starting 3 days prior to pharmacokinetic (PK) sampling:

    • Garlic supplements and methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.), apples or apple juice
  10. Willingness to abstain from over-the-counter herbal medications for the duration of the study
  11. Must be a non-smoker
  12. Willingness to abstain from vigorous physical exercise during intensive PK days; Days 10 and 24
  13. Reasonable probability for completion of the study

Exclusion criteria

Exclusion Criteria:

  1. Female subjects of who:

    • Have positive serum pregnancy test
    • Have not been using a barrier method of for at least 3 months prior to participation in the study
    • Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial
    • Are breast-feeding.
  2. Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 1 and for the duration of the study.

    Due to long half-life, subjects using Depo-Provera® within six months prior to Day 1 will be excluded from participation in this study

  3. Use of hormone replacement therapy within 1 month prior to Day 1 and anytime during the study
  4. Participation in another trial with an medicine within 2 months prior to Day 1 of this study
  5. Use of any medication listed in Appendix 10.5 within 30 days prior to Day 1 of this study
  6. Administration of antibiotics within 15 days prior to Day 1 and anytime during the study
  7. History of acute illness within 60 days prior to Day 1

    • Subjects will be excluded for acute illnesses that occurred more than 60 days prior to Day 1 if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
  8. Have serological evidence of virus (HBV) or virus (HCV)
  9. Have serological evidence of exposure to
  10. Alcohol or substance abuse within 1 year prior to screening or during the study
  11. Blood or plasma donations within 30 days prior to Day 1 or during the study
  12. Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV, RTV or EFV to the subject
  13. History of a psychiatric disorder that required pharmacological or other psychological treatment
  14. Subjects who have taken (within 7 days prior to Day 1) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the sponsor's clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications
  15. Known to sulphonamide class of drugs
  16. Known hypersensitivity to TPV, RTV, EFV or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
  17. Known elevated liver enzymes in past trials with any compound
  18. Inability to adhere to the protocol
  19. Cautions or warnings in the RTV and EFV package insert which, in the opinion of the investigator, constitute grounds for subject exclusion
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    TPV/RTV/EFV

    tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23

    Drug: Tipranavir · Drug: Ritonavir · Drug: Efavirenz

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration at steady state (Cmax)

    Time frame: up to 12 hours after drug administration

  2. Drug concentration in plasma at 12 hours after administration (Cp12h)

    Tipranavir (TPV)

    Time frame: up to 12 hours after drug administration

  3. Last measured drug concentration in plasma (Cplast)

    Ritonavir (RTV)

    Time frame: up to 12 hours after drug administration

  4. Area under plasma concentration time curve from 0-12 hours (AUC0-12h)

    Time frame: up to 12 hours after drug administration

Secondary outcomes

  1. Trough plasma concentration (Cmin)

    Time frame: before drug administration

  2. Time from dosing to the maximum concentration (tmax)

    Time frame: up to 12 hours after drug administration

  3. Elimination half-life (t1/2)

    Time frame: up to 12 hours after drug administration

  4. Oral clearance (CL/F)

    Time frame: up to 12 hours after drug administration

  5. Volume of distribution (Vz/F)

    Time frame: up to 12 hours after drug administration

  6. Number of subjects with adverse events

    Time frame: up to 38 days after first drug administration

  7. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 38 days after first drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2014
First posted
Aug 27, 2014
Start
Apr 2006
Primary completionActual
Jul 2006
Last update
Aug 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02226991
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Apr 2006
Primary completion
Jul 2006
Last update
Aug 27, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Efavirenz

Start the discussion